skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

1196 Three and Five-Year Outcomes for Teduglutide in Intestinal Failure

Puello, Frances ; Wall, Elizabeth ; Herlitz, Jean ; Lozano, Scott ; Reynolds, Valerie ; Widlicka, Annie ; McDonald, Edwin K. ; Semrad, Carol ; Micic, Dejan

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S672-S673 [Periódico revisado por pares]

Sem texto completo

Citações Citado por
  • Título:
    1196 Three and Five-Year Outcomes for Teduglutide in Intestinal Failure
  • Autor: Puello, Frances ; Wall, Elizabeth ; Herlitz, Jean ; Lozano, Scott ; Reynolds, Valerie ; Widlicka, Annie ; McDonald, Edwin K. ; Semrad, Carol ; Micic, Dejan
  • É parte de: The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S672-S673
  • Descrição: INTRODUCTION: Intestinal failure (IF) results from a variety of causes leading to need for parenteral support (PS). Teduglutide was approved for adult patients requiring PS in December 2012. Teduglutide is a glucagon-like peptide 2 (GLP-2) analogue that aids in the growth of the intestinal villi and reduces gastric emptying, thereby promoting absorption of fluids, calories and electrolytes. Previous studies have shown that teduglutide has decreased PS use by >20% at 12 and 24 months. Long term efficacy data has not been studied. Our aim is to present 3 and 5 year patient outcomes on teduglutide. METHODS: Data was collected retrospectively from a single center including patients requiring PS that also received teduglutide between 3/1/13 and 5/1/19. Patient demographics including length of small intestine, presence/absence of an ileocecal valve and duration of PS was recorded. Outcomes of teduglutide therapy were recorded at 12, 24, 36, and 60 months with respect to PS volume, calories, days per week of PS use, and ability to stop PS. Response to teduglutide was defined as a > 20% reduction in PS compared to baseline volume. Data were analyzed using Fischer’s exact test for categorical variables and one-way ANOVA for comparison of means followed by Dunnett’s test. RESULTS: Patient demographic and IF etiology data is presented in Table 1. Eighteen patients were included in the final analysis. Indications for stopping teduglutide are listed in Table 2. Baseline and longitudinal PS requirements, weight trends and responders are shown in Table 3. Among individuals with follow-up, the number of responders was 11/16 (69%) at 12 months, 10/13 (77%) at 24 months, 7/10 (70%) at 36 months and 3/3 (100%) at 60 months. Among responders, the presence of a colon in continuity, ileocecal valve, or length of remaining small bowel did not affect TPN requirement ( P > 0.05 for all comparisons). Ten out of 16 (63%) patients had a one or more day decrease in TPN frequency at 12 months, 9/13 (69%) at 24 months, 6/10 (60%) at 36 months, and 3/3 (100%) at 60 months. Change in PS volume and days of PS per week were significantly lower at 24 months and 60 months (Table 3). CONCLUSION: Previous studies have shown that teduglutide therapy decreases PS requirements in patients requiring PS over 12 and 24 months. We found that patients achieving reductions in PS requirements can successfully continue teduglutide therapy for up to 5 years with continued reductions in PS volume and days.
  • Idioma: Inglês
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.